Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092180 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL26292093 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL7677587 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL22717025 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL7676443 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL30980495 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL31395742 | 1.00 | TLR2 (0.34) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL20552587 | 0.98 | STING1 (0.35) | TLR2TLR1STING1TSHRHDAC3 | |
| SCHEMBL27410618 | 0.93 | ALDH1A1 (0.40) | TLR2TLR1TSHRHDAC1HDAC2 | |
| SCHEMBL5735427 | 0.92 | STING1 (0.37) | TLR2TLR1STING1TSHRHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3947368-B1 | BIFUNCTIONAL COMPOUNDS COMPRISING A CDK2/5 LIGAND, A LINKER AND A E3 UBIQUITIN LIGASE BINDING DEGRON FOR THE TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4419520-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3892272-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-20 | — | — | US | disclosed |
| CN-109475528-B | Bifunctional molecules for EGFR degradation and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3892272-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2017185036-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | TLR2 2837/4885TLR1 3828/4885STING1 3051/4885 |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | TLR2 2837/4885TLR1 3828/4885STING1 3051/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | TLR2 4179/4885TLR1 4298/4885STING1 2251/4885 |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | CDK2, CDK5, CDK5R1 | TLR2 4023/4885TLR1 4658/4885STING1 4117/4885 |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | ADRM1, PSMD7, UBQLN2 | TLR2 3967/4885TLR1 4212/4885STING1 2464/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | TLR2 1153/4885TLR1 534/4885STING1 3917/4885 |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | TLR2 2837/4885TLR1 3828/4885STING1 3051/4885 |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | TLR2 2837/4885TLR1 3828/4885STING1 3051/4885 |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | TLR2 2837/4885TLR1 3828/4885STING1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.